The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech
In addition to these programs, BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules
Ryvu will receive €40 million from BioNTech, comprised of a €20 million upfront payment and an equity investment of €20 million, as well as research funding. Additionally, Ryvu is eligible to receive R&D and commercial milestone payments in addition to low single-digit royalties
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.